Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint

PURPOSE: CEP-701 is a potent inhibitor of trk receptors that causes cell death in prostate cancer (PC) models. CEP-701 binds to serum proteins and a preprostatectomy study was performed to assess prostate tissue penetration and clinical response to CEP-701. METHODS: Growth assays and Western blot an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Collins, Connie, Carducci, Michael A., Eisenberger, Mario A., Isaacs, John T., Partin, Alan W., Pili, Roberto, Sinibaldi, Victoria J., Walczak, Janet S., Denmeade, Samuel R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4124640/
https://ncbi.nlm.nih.gov/pubmed/17786033
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller